News Search Results
May 07, 2025, 07:00 ET Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
Ganesh, Partner at Obvious Ventures. "At Obvious, we believe AI is ushering in a new scientific method, accelerating innovation across fields like biotechnology and healthcare. Inductive embodies this shift, showing how these approaches can drive real-world breakthroughs that have the potential to fundamentally
More news about: Inductive Bio, Inc.
May 07, 2025, 06:30 ET BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency
More news about: Bio-Techne Corporation
May 07, 2025, 06:30 ET BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and
More news about: Bio-Techne Corporation
May 07, 2025, 06:15 ET Epson Robots Invests in Blank Beauty to Bring Automation and Retailtainment to the Consumer Space
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
May 07, 2025, 04:21 ET Mana.bio Presents New Data Demonstrating the Power of AI towards Unlocking the Potential of RNA Medicine
NEW ORLEANS, La., May 7, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company leveraging artificial intelligence (AI) and nanotechnology for targeted RNA delivery, today announced three poster presentations at the
More news about: Mana.bio
May 07, 2025, 02:38 ET BPC Instruments reports results for Q1 2025
instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing
More news about: BPC Instruments AB
May 07, 2025, 02:08 ET The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China
anti-tumor diagnosis and treatment and cerebrocardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and take technological innovation as the driving
More news about: Grand Pharmaceutical Group Limited
May 07, 2025, 02:00 ET MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled
More news about: MetaVia Inc.
May 06, 2025, 19:00 ET Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S.
More news about: Adcentrx Therapeutics
May 06, 2025, 18:30 ET Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
May 06, 2025, 18:30 ET Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain following ocular surgery
www.apotex.com. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Apotex Inc.
May 06, 2025, 18:16 ET Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board
More news about: Curis, Inc.
May 06, 2025, 17:00 ET Ginkgo Bioworks Reports First Quarter 2025 Financial Results
commitment to achieving our cost reduction targets." Recent Business Highlights & Strategic Positioning Biotechnology remains a critical emerging technology area in the US and Ginkgo is well positioned to provide biosecurity and R&D servicesOffice
More news about: Ginkgo Bioworks
May 06, 2025, 16:01 ET Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first quarter ended March 31,
More news about: Rigel Pharmaceuticals, Inc.
May 06, 2025, 16:01 ET HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
May 06, 2025, 10:30 ET WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, priced a best efforts offering of securities as described
More news about: WallachBeth Capital LLC
May 06, 2025, 09:30 ET Specific Biologics Inc. to Present Dualase® Genome Editing for the Precise Removal of Pathogenic Repeats in Repeat Expansion Disorders at the 28th Annual American Society for Gene and Cell Therapy Meeting
TORONTO, May 6, 2025 /PRNewswire/ - Specific Biologics Inc., a biotechnology company advancing industry leading genome editing therapies, today announced it will present new preclinical data at the 28th Annual Meeting of
More news about: Specific Biologics Inc.
May 06, 2025, 09:05 ET Wobble Genomics Announces Appointment of Dr. Dietrich A. Stephan as Chairman of the Board of Directors
EDINBURGH, Scotland, May 6, 2025 /PRNewswire/ -- Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA)
More news about: Wobble Genomics Ltd.
May 06, 2025, 09:00 ET Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors
driven by Formosa." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's flagship program, APP13007, is a novel topical formulation
More news about: Formosa Pharmaceuticals Inc.,
May 06, 2025, 08:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
May 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
May 06, 2025, 08:00 ET Benuvia Operations Signs Research & Development and Manufacturing Agreement with Trait Biosciences to Advance Next-Generation Cannabinoid-Based Products
BiosciencesTrait Biosciences is a science-focused research organization focused on developing truly water-soluble hemp-derived cannabinoids, leveraging biotechnology and chemical synthesis processes, and qualifying manufacturability, thereby providing our customers with unique and differentiated ingredients for
More news about: Benuvia Operations, LLC
May 06, 2025, 08:00 ET Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
May 06, 2025, 08:00 ET Curis Provides First Quarter 2025 Business Update
Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update
More news about: Curis, Inc.
May 06, 2025, 07:45 ET Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate
More news about: Heron Therapeutics, Inc.
May 06, 2025, 07:30 ET Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company,
More news about: Heron Therapeutics, Inc.